Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study

Mao, YY; Cai, HC; Shen, KN; Chang, L; Zhang, L; Zhang, Y; Feng, J; Wang, W; Yang, C; Zhu, TN; Duan, MH; Zhou, DB; Cao, XX; Li, J

Cao, XX; Li, J (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Hematol, Beijing 100730, Peoples R China.;Cao, XX; Li, J (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Beijing, Peoples R China.

ANNALS OF HEMATOLOGY, 2022; 101 (4): 831

Abstract

Idarubicin 12 mg/m(2) has been recommended as a standard induction therapy for acute myeloid leukemia (AML). It is unknown whether a higher dose of id......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索